Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H14ClNO |
| Molecular Weight | 211.688 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(CCNCC1)C2=CC=C(Cl)C=C2
InChI
InChIKey=LZAYOZUFUAMFLD-UHFFFAOYSA-N
InChI=1S/C11H14ClNO/c12-10-3-1-9(2-4-10)11(14)5-7-13-8-6-11/h1-4,13-14H,5-8H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1599504Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24827597 | http://www.hmdb.ca/metabolites/HMDB60902
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1599504
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24827597 | http://www.hmdb.ca/metabolites/HMDB60902
4-(4-Chlorophenyl)-4-piperidinol (CPPO) is one of haloperidol metabolite. Neurotoxicity studies in frogs, which have been used to detect N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) action, showed that CPPO did not mimic the neurotoxicity of MPTP but caused a delayed and persistent freezing action in Rana pipiens frogs. It is proposed that this action may contribute to some of the delayed side-effects associated with haloperidol therapy.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24827597 |
9090.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| 4-(4-Chloro-phen-yl)-4-hy-droxy-piperidinium maleate maleic acid solvate. | 2010-07-14 |
|
| Bis[4-(4-chloro-phen-yl)-4-hydroxy-piperidinium] dipicrate dimethyl sulfoxide solvate. | 2010-04-30 |
|
| 4-(4-Chloro-phen-yl)piperidin-4-ol. | 2010-02-06 |
|
| [Chemical toxicological analysis of haloperidol metabolite 4-(4-chlorophenyl)-4-hydroxypipiridine in urine by high-performance liquid chromatography]. | 2009-04-18 |
|
| Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. | 2006-12 |
|
| Identification of a new functional target of haloperidol metabolite: implications for a receptor-independent role of 3-(4-fluorobenzoyl) propionic acid. | 2006-10 |
|
| Sensitive determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, in a rat biological sample by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. | 2006-09 |
|
| Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection. | 2006-02 |
|
| Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. | 2005-06 |
|
| Synthesis and pharmacological activity of 4-(4'-(chlorophenyl)-4-hydroxypiperidine) derivatives. | 2005-01 |
|
| Salt formation in solid dispersions consisting of polyacrylic acid as a carrier and three basic model compounds resulting in very high glass transition temperatures and constant dissolution properties upon storage. | 2004-10-18 |
|
| Liquid chromatographic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine. | 2002-08-25 |
|
| Comparison of SSI with APCI as an interface of HPLC-mass spectrometry for analysis of a drug and its metabolites. | 2002-03 |
|
| In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. | 2001-12 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24827597
Cell membranes (D2L-FlpIn CHO, 3 μg) were incubated with varying concentrations of test compound 7 (4-(4-Chlorophenyl)-4-piperidinol) in binding buffer (20 mM HEPES, 100 mM NaCl, 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA, pH 7.4) containing 0.05 nM of [3H]spiperone and 100 μM GppNHp to a final volume of 1 mL and were incubated at 37 °C for 3 h. Binding was terminated by fast-flow filtration over GF/B membranes using a Brandel harvester followed by three washes with ice-cold 0.9% NaCl. Bound radioactivity was measured in a Tri-Carb 2900TR liquid scintillation counter (PerkinElmer).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
89568
Created by
admin on Mon Mar 31 21:23:31 GMT 2025 , Edited by admin on Mon Mar 31 21:23:31 GMT 2025
|
PRIMARY | |||
|
UND92FKS0W
Created by
admin on Mon Mar 31 21:23:31 GMT 2025 , Edited by admin on Mon Mar 31 21:23:31 GMT 2025
|
PRIMARY | |||
|
DTXSID7057733
Created by
admin on Mon Mar 31 21:23:31 GMT 2025 , Edited by admin on Mon Mar 31 21:23:31 GMT 2025
|
PRIMARY | |||
|
254-479-8
Created by
admin on Mon Mar 31 21:23:31 GMT 2025 , Edited by admin on Mon Mar 31 21:23:31 GMT 2025
|
PRIMARY | |||
|
38282
Created by
admin on Mon Mar 31 21:23:31 GMT 2025 , Edited by admin on Mon Mar 31 21:23:31 GMT 2025
|
PRIMARY | |||
|
39512-49-7
Created by
admin on Mon Mar 31 21:23:31 GMT 2025 , Edited by admin on Mon Mar 31 21:23:31 GMT 2025
|
PRIMARY |
PARENT (METABOLITE INACTIVE)
SUBSTANCE RECORD